Cambridge Isotope Laboratories, Inc. (CIL) has unveiled its new ISOAPI-D product line during the CPhI Frankfurt 2025 trade show, reaffirming its commitment to innovation in the supply of deuterated reagents for the pharmaceutical industry. This offering is characterized by being global and secure, meeting the highest quality standards, which enables a more agile and efficient development of active pharmaceutical ingredients (APIs).
CIL’s extensive manufacturing network includes facilities in North America, Europe, and Asia, ensuring its pharmaceutical partners a diversified and resilient supply chain. All reagents in the ISOAPI-D line are produced in ISO 9001-certified plants, thereby ensuring compliance with quality standards and complete traceability throughout the entire production process.
Highlighted products in ISOAPI-D include heavy water (D₂O), which CIL sources exclusively from authorized suppliers. This compound is fully traceable and free from tritium, complying with the stringent regulatory and safety requirements demanded by the pharmaceutical sector. Additionally, the range includes advanced intermediates that optimize synthetic routes, reducing both the number of steps in the synthesis and improving production efficiency, thereby lowering costs and speeding up the time to market for new treatments.
Since its founding in 1981, CIL has established itself as a reliable supplier of high-quality deuterated materials for leading pharmaceutical and biotechnology companies worldwide. The recent introduction of ISOAPI-D underscores the company’s dedication to quality and reliability, ensuring its customers a secure supply of essential reagents and mitigating operational risks in new product development.
Tasha Agreste, Director of Business Development for Deuterated Reagent Applications at CIL, stated: “ISOAPI-D represents a significant advancement in our ongoing mission to support pharmaceutical innovation. With our expanded manufacturing capabilities and rigorous quality standards, CIL positions itself as a reliable partner for the evolving needs of the industry.”
Those interested in learning more about ISOAPI-D can visit CIL’s booth No. 2.0G2 at CPhI Frankfurt, taking place from October 28 to 30. CIL, a subsidiary of Otsuka Pharmaceutical in Japan, stands as one of the largest manufacturers and global suppliers of stable isotopes, supporting a wide range of applications in research, diagnostics, and pharmacology.
Referrer: MiMub in Spanish